Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 670

1.

'Looking beyond survival to define therapeutic value in acute myeloid leukemia'.

Estey E.

Leuk Lymphoma. 2019 Jan 10:1-3. doi: 10.1080/10428194.2018.1543886. [Epub ahead of print] No abstract available.

PMID:
30628507
2.

Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come.

Hitzler J, Estey E.

Haematologica. 2019 Jan;104(1):7-9. doi: 10.3324/haematol.2018.205948. No abstract available.

3.

Outpatient induction and consolidation care strategies in acute myeloid leukemia.

Halpern AB, Walter RB, Estey EH.

Curr Opin Hematol. 2018 Dec 24. doi: 10.1097/MOH.0000000000000481. [Epub ahead of print]

PMID:
30585894
4.

Phase 1/2 trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Estey EH, Walter RB.

Haematologica. 2018 Nov 8. pii: haematol.2018.204792. doi: 10.3324/haematol.2018.204792. [Epub ahead of print]

5.

Acute myeloid leukemia: 2019 update on risk-stratification and management.

Estey EH.

Am J Hematol. 2018 Oct;93(10):1267-1291. doi: 10.1002/ajh.25214.

PMID:
30328165
6.

Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.

Othus M, Sekeres MA, Nand S, Garcia-Manero G, Appelbaum FR, Erba HP, Estey E.

Leukemia. 2018 Oct 12. doi: 10.1038/s41375-018-0275-x. [Epub ahead of print]

PMID:
30315234
7.

Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.

Othus M, Estey EH, Garcia-Manero G, Wood BL, Stirewalt DL, Godwin JE, Weick JK, Anderson JE, Appelbaum FR, Erba HP, Walter RB.

Leukemia. 2018 Oct 12. doi: 10.1038/s41375-018-0274-y. [Epub ahead of print] No abstract available.

PMID:
30315233
8.

A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.

Buckley SA, Percival ME, Othus M, Halpern AB, Huebner EM, Becker PS, Shaw C, Shadman M, Walter RB, Estey EH.

Leuk Lymphoma. 2018 Oct 2:1-7. doi: 10.1080/10428194.2018.1516036. [Epub ahead of print]

PMID:
30277112
9.

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML).

Acharya UH, Halpern AB, Wu QV, Voutsinas JM, Walter RB, Yun S, Kanaan M, Estey EH.

J Drug Assess. 2018 Jul 10;7(1):51-53. doi: 10.1080/21556660.2018.1492925. eCollection 2018.

10.

New drugs in AML: uses and abuses.

Estey EH, Gale RP, Sekeres MA.

Leukemia. 2018 Jul;32(7):1479-1481. doi: 10.1038/s41375-018-0168-z. Epub 2018 Jun 6. No abstract available.

PMID:
29875431
11.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.

Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.

PMID:
29859851
12.

Incorporating Physical Function and Cognition Into Mortality Risk Assessment for Acute Myeloid Leukemia-Reply.

Sorror ML, Storer BE, Estey EH.

JAMA Oncol. 2018 Jul 1;4(7):1014-1015. doi: 10.1001/jamaoncol.2018.0677. No abstract available.

PMID:
29799988
13.

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, Walter RB.

Leukemia. 2018 Apr 17. doi: 10.1038/s41375-018-0135-8. [Epub ahead of print]

14.

Time to repeal and replace response criteria for acute myeloid leukemia?

Bloomfield CD, Estey E, Pleyer L, Schuh AC, Stein EM, Tallman MS, Wei A.

Blood Rev. 2018 Sep;32(5):416-425. doi: 10.1016/j.blre.2018.03.006. Epub 2018 Mar 27. Review.

15.

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.

Zhou Y, Othus M, Walter RB, Estey EH, Wu D, Wood BL.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1615-1620. doi: 10.1016/j.bbmt.2018.04.017. Epub 2018 Apr 21.

PMID:
29684564
16.

Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development.

Seo J, Smith BD, Estey E, Voyard E, O' Donoghue B, Bridges JFP.

Curr Med Res Opin. 2018 Dec;34(12):2031-2039. doi: 10.1080/03007995.2018.1456414. Epub 2018 Apr 27.

PMID:
29565196
17.

Widespread use of measurable residual disease in acute myeloid leukemia practice.

Epstein-Peterson ZD, Devlin SM, Stein EM, Estey E, Tallman MS.

Leuk Res. 2018 Apr;67:92-98. doi: 10.1016/j.leukres.2018.02.006. Epub 2018 Feb 13.

PMID:
29482173
18.

A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.

Lee SI, Celik S, Logsdon BA, Lundberg SM, Martins TJ, Oehler VG, Estey EH, Miller CP, Chien S, Dai J, Saxena A, Blau CA, Becker PS.

Nat Commun. 2018 Jan 3;9(1):42. doi: 10.1038/s41467-017-02465-5.

19.

Allogeneic Transplantation for Acute Myelogenous Leukemia in CR1.

Estey E.

Biol Blood Marrow Transplant. 2018 Feb;24(2):205-206. doi: 10.1016/j.bbmt.2017.12.773. Epub 2017 Dec 14. No abstract available.

PMID:
29248740
20.

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.

Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, Percival MM, Hendrie PC, Medeiros BC, Chiarella MT, Louie AC, Estey EH.

Haematologica. 2018 Mar;103(3):e106-e109. doi: 10.3324/haematol.2017.182642. Epub 2017 Dec 14. No abstract available.

21.

Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.

Percival ME, Estey E.

Clin Adv Hematol Oncol. 2017 Aug;15(8):632-642. Review.

PMID:
28949951
22.

Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH.

JAMA Oncol. 2017 Dec 1;3(12):1675-1682. doi: 10.1001/jamaoncol.2017.2714.

23.

Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?

Zhou Y, Wood BL, Walter RB, Becker PS, Percival ME, Bar M, Shaw C, Gardner K, Hendrie P, Abkowitz J, Appelbaum FR, Estey E.

Leukemia. 2017 Nov;31(11):2536-2537. doi: 10.1038/leu.2017.263. Epub 2017 Aug 18. No abstract available.

PMID:
28819284
24.

A case of indolent AML with five-year survival without treatment.

Bezerra ED, Smith H, Estey E.

Leuk Lymphoma. 2018 Feb;59(2):519. doi: 10.1080/10428194.2017.1330471. Epub 2017 Jun 22. No abstract available.

PMID:
28637370
25.

Day 14 bone marrow examination in the management of acute myeloid leukemia.

Terry CM, Shallis RM, Estey E, Lim SH.

Am J Hematol. 2017 Oct;92(10):1079-1084. doi: 10.1002/ajh.24818. Epub 2017 Jul 19. Review.

26.

Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival MM, Estey EH, Stirewalt DL, Walter RB.

Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30.

27.

Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.

Chen X, Othus M, Wood BL, Walter RB, Percival MM, Becker PS, Hendrie PC, Appelbaum FR, Estey EH.

Leuk Lymphoma. 2017 Nov;58(11):2717-2719. doi: 10.1080/10428194.2017.1307359. Epub 2017 Mar 28. No abstract available.

PMID:
28351184
28.

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G.

Leukemia. 2017 Jul;31(7):1659. doi: 10.1038/leu.2017.85. Epub 2017 Mar 24.

29.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

30.

How good are we at predicting the fate of someone with acute myeloid leukaemia?

Estey E, Gale RP.

Leukemia. 2017 Jun;31(6):1255-1258. doi: 10.1038/leu.2017.56. Epub 2017 Mar 17. No abstract available.

PMID:
28303892
31.

Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.

Qu X, Othus M, Davison J, Wu Y, Yan L, Meshinchi S, Ostronoff F, Estey EH, Radich JP, Erba HP, Appelbaum FR, Fang M.

Cancer. 2017 Jul 1;123(13):2472-2481. doi: 10.1002/cncr.30626. Epub 2017 Feb 21.

32.

Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Percival ME, Lai C, Estey E, Hourigan CS.

Blood Rev. 2017 Jul;31(4):185-192. doi: 10.1016/j.blre.2017.01.003. Epub 2017 Feb 2. Review.

33.

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F.

Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.

34.

Acute Myeloid Leukemia - Many Diseases, Many Treatments.

Estey E.

N Engl J Med. 2016 Nov 24;375(21):2094-2095. No abstract available.

PMID:
27959719
35.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.

36.

Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia?

Estey E.

Best Pract Res Clin Haematol. 2016 Dec;29(4):324-328. doi: 10.1016/j.beha.2016.10.003. Epub 2016 Oct 18. Review.

PMID:
27890254
37.

Acute myeloid leukemia therapy and the chosen people.

Estey E, Gale RP.

Leukemia. 2017 Feb;31(2):269-271. doi: 10.1038/leu.2016.306. Epub 2016 Nov 11. No abstract available.

PMID:
27833103
38.

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G.

Leukemia. 2017 Feb;31(2):318-324. doi: 10.1038/leu.2016.303. Epub 2016 Oct 31. Erratum in: Leukemia. 2017 Jul;31(7):1659.

PMID:
27795561
39.

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ.

Leukemia. 2017 Mar;31(3):697-704. doi: 10.1038/leu.2016.254. Epub 2016 Sep 22.

40.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Othus M, Estey E, Gale RP.

N Engl J Med. 2016 Aug 11;375(6):e9. doi: 10.1056/NEJMc1603847. No abstract available.

PMID:
27509127
41.

Acute myeloid leukemia: 2016 Update on risk-stratification and management.

Estey E.

Am J Hematol. 2016 Aug;91(8):824-46. doi: 10.1002/ajh.24439. Review.

42.

Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial.

Delaney C, Milano F, Cicconi L, Othus M, Becker PS, Sandhu V, Nicoud I, Dahlberg A, Bernstein ID, Appelbaum FR, Estey EH.

Lancet Haematol. 2016 Jul;3(7):e330-9. doi: 10.1016/S2352-3026(16)30023-0. Epub 2016 Jun 7.

PMID:
27374466
43.

Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study.

Eapen LJ, Jones E, Kassouf W, Lambert C, Morgan SC, Moussa M, Nam R, Parliament M, Russell L, Saad F, Siemens DR, Souhami L, Szumacher E, Tyldesley S, Xu Y, Zbieranowski I, Breau RH, Belanger E, Black P, Estey E, Bowan J, Bora B, Brundage M, Chung P, Fleshner N, Evans A, Bauman G, Izawa J, Davidson C, Brimo F.

Can Urol Assoc J. 2016 Mar-Apr;10(3-4):90-4. doi: 10.5489/cuaj.3456.

44.

Acute myeloid leukaemia.

Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC.

Nat Rev Dis Primers. 2016 Mar 10;2:16010. doi: 10.1038/nrdp.2016.10. Review.

PMID:
27159408
45.

Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.

Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, Erba HP, Walter RB.

Leukemia. 2016 Oct;30(10):2080-2083. doi: 10.1038/leu.2016.120. Epub 2016 May 2. No abstract available.

46.

Moving toward targeted therapies in acute myeloid leukemia.

Gao W, Estey E.

Clin Adv Hematol Oncol. 2015 Nov;13(11):748-54. Review.

PMID:
27058701
47.

Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.

Othus M, Mukherjee S, Sekeres MA, Godwin J, Petersdorf S, Appelbaum FR, Erba H, Estey E.

Leukemia. 2016 Aug;30(8):1779-80. doi: 10.1038/leu.2016.48. Epub 2016 Feb 29. No abstract available.

48.

Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI.

Othus M, van Putten W, Lowenberg B, Petersdorf SH, Nand S, Erba H, Appelbaum F, Hills R, Russell N, Burnett A, Estey E.

Haematologica. 2016 Jul;101(7):e284-6. doi: 10.3324/haematol.2015.138552. Epub 2016 Mar 24. No abstract available.

49.

Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.

Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.

Leukemia. 2016 Jul;30(7):1456-64. doi: 10.1038/leu.2016.46. Epub 2016 Feb 29.

50.

Variability in management of hematologic malignancy patients with venous thromboembolism and chemotherapy-induced thrombocytopenia.

Samuelson BT, Gernsheimer T, Estey E, Garcia DA.

Thromb Res. 2016 May;141:104-5. doi: 10.1016/j.thromres.2016.03.011. Epub 2016 Mar 12. No abstract available.

Supplemental Content

Support Center